What is Sotalol Drug Market?
Sotalol drug is used to treat a serious possibly life-threatening type of fast heartbeat called sustained ventricular tachycardia. It is also used to treat certain fast/irregular heartbeats (atrial fibrillation/flutter) in patients with severe symptoms such as weakness and shortness of breath. Sotalol helps to lessen these symptoms. It slows the heart rate and helps the heart to beat more normally and regularly. This medication is both a beta-blocker and an anti-arrhythmic.
The market study is being classified, by Application (Ventricular Arrhythmias, Atrial Fibrillation/Flutter and Supraventricular Arrhythmias) and major geographies with country level break-up.
Bayer AG (Germany), Mylan N.V. (United States), Arbor Pharmaceuticals (United States), Upsher-Smith Laboratories (United States), AltaThera Pharmaceuticals (United States), Teva (Israel), Apotex (Canada) and Epic Pharma (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sotalol Drug market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Sotalol Drug market by Type, Application and Region.
On the basis of geography, the market of Sotalol Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Various Diseases in Ageing Population across the Globe
- Rising Chronic Disease Ventricular Arrhythmias
- Increased use of Sotalol Drug for Heart Beating
- Various Side Effects like Hypotension, Heart Failure
- Technological Development and Advancement in Sotalol Drug
- Strict Government Regulation Regarding Sotalol Drug
Market Leaders and some development strategies
Recently, Mylan Laboratories Inc. has announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sotalol Hydrochloride Tablets USP (AF), 80mg, 120mg, and 160mg.
On 10th March 2020 AltaThera Pharmaceuticals, LLC has announced that the US Food and Drug Administration (FDA) has approved new indications for Sotalol IV in AFib patients. "The new indications for Sotalol IV represent a significant advance that decreases the length of stay for new patients starting sotalol for AFib".
Key Target AudienceSotalol Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase